Disclosure of HIV Status and Adherence to Daily Drug Regimens Among HIV-infected Children in Uganda
- 1.2k Downloads
Pediatric adherence to daily drug regimens has not been widely assessed in Africa where majority of HIV infected children live. Using in-depth interviews of 42 HIV-infected children taking ART and/or cotrimoxazole prophylaxis, and 42 primary caregivers, at a comprehensive HIV/AIDS clinic in Uganda, we evaluated their adherence experiences for purposes of program improvement. Daily drug regimens provided by the pediatric clinic included cotrimoxazole prophylaxis as well as ART and cotrimoxazole combined. Complete disclosure of HIV status by caregivers to children and strong parental relationships were related to good adherence. Structural factors including poverty and stigma were barriers to adherence even for children who had had complete disclosure and a supportive relationship with a parent. To ensure adherence to life-extending medications, our findings underscore the need for providers to support caregivers to disclose, provide on-going support and maintain open communication with HIV-infected children taking cotrimoxazole prophylaxis and ART.
KeywordsPediatrics AIDS Adherence Antiretrovirals Cotrimoxazole
We thank Mildmay Centre staff and clients and Centres for Disease Control staff for all their time and efforts. E. Ezati, R. Nasaba, J. Kalyebara, R. Ingabire and M. Butamanya conducted the interviews, R. Apondi, S. Nakayiwa and F. Bloom with data analysis and S. Bechange and R. Batamwita assisted with data management. We also thank G. Rutherford, R. King and R. Stall, for their comments on earlier versions of this manuscript and T. Wamala for her assistance with the references.
- African Network for the Care of Children Affected by AIDS (2004). Handbook on paediatric AIDS in Africa.Google Scholar
- Blasini, I., Chantry, C., Cruz, C., Ortiz, L., Salabarria, I., Scalley, N., & Matos, B. (2004). Disclosure model for pediatric patients living with HIV in Puerto Rico: Design, implementation, and evaluation. Journal of Developmental and Behavioral Pediatrics, 25, 181–189.PubMedCrossRefGoogle Scholar
- Chintu, C., Bhat, G. J., Walker, A. S., Mulenga, V., Sinyinza, F., Lishimpi, K., & Farrelly, L. (2004). Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): A double-blind randomised placebo-controlled trial. Lancet, 364, 1865–1871.PubMedCrossRefGoogle Scholar
- Elise, A., France, A. M., Louise, W. M., Bata, D., Francois, R., Roger, S., & Philippe, M. (2005). Assessment of adherence to highly active antiretroviral therapy in a cohort of African HIV-infected children in Abidjan, Cote d’Ivoire. Journal of Acquired Immune Deficiency Syndromes, 40, 498–500.PubMedCrossRefGoogle Scholar
- Martinez, J., Bell, D., Camacho, R., Henry-Reid, L. M., Bell, M., Watson, C., & Rodriguez, F. (2000). Adherence to antiviral drug regimens in HIV-infected adolescent patients engaged in care in a comprehensive adolescent and young adult clinic. Journal of the National Medical Association, 92, 55–61.PubMedGoogle Scholar
- Shingadia, D., Viani, R. M., Yogev, R., Binns, H., Dankner, W. M., Spector, S. A., & Chadwick, E. G. (2000). Gastrostomy tube insertion for improvement of adherence to highly active antiretroviral therapy in pediatric patients with human immunodeficiency virus. Pediatrics, 105, E80.PubMedCrossRefGoogle Scholar
- UNAIDS. (2004). Report on the global HIV/AIDS epidemic: 4th global report. [Retrieved from: http://www.unaids.org/bangkok2004/GAR2004_pdf/UNAIDSGlobalReport2004_en.pdf].Google Scholar
- World Health Organization. (2006). Who expert consultation on cotrimoxazole prophylaxis in HIV infection. [Retrieved from: http://www.womenchildrenhiv.org].Google Scholar